Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers - Wikidata - wikimedia - TriplyDB

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

http://www.wikidata.org/entity/Q36916140

about

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers The Consequences of a BRCA Mutation in Women Challenging and complex decisions in the management of the BRCA mutation carrier Management of Menopausal Symptoms.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Genetically engineered ERα-positive breast cancer mouse models.Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer Clinical management of hereditary breast cancer syndromes.Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Genetics of breast cancer: a topic in evolution.Online tool to guide decisions for BRCA1/2 mutation carriers.The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review Impact of risk-reducing salpingo-oophorectomy in premenopausal women.Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.Neuroprotective effect of exogenous melatonin on dopaminergic neurons of the substantia nigra in ovariectomized rats.Salpingectomy to prevent ovarian cancer: A Countercurrents Series Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations.Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk.HRT in difficult circumstances: are there any absolute contraindications?Hormone replacement therapy and the risk of breast cancer.BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.Pathology of hereditary breast cancer.Aryl Hydrocarbon Receptor Diet and Breast Cancer Risk.Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy

P2860

Q24654487-3A9FE9C8-9CFF-4BA1-BEF3-8C5BA6E3E4E3 Q26777891-38C3E5D3-CCED-4C0B-BC78-32539CD76D24 Q27026559-FAB2357E-82B6-4765-A0BB-3B3E1CF791C6 Q27318357-65003D78-127F-48FD-AF1E-02FFF96A8578 Q33564013-1899A227-1C77-4A86-81BA-44DEBF16AEBF Q33578641-E68E8A4B-6160-4A6D-B01C-B7B2A4EE6757 Q33633402-B6EED460-E711-4CA2-9EF3-1412D70B19DE Q33845209-4917F94F-6DA2-46BC-B884-738FDCFF3E97 Q34125241-FB528457-FDF7-4C2B-B690-2190E05EA33F Q34152848-467E6B8F-3A2B-4AEA-9A73-F6FFE2297740 Q34167563-51162C27-8626-46AD-B741-53C830038F97 Q34172655-AEF00367-95FF-465B-A7A3-09AB62A9FF34 Q35179515-EF062516-5AF8-48FB-9122-1D7A544E3843 Q35687632-0AF14F11-CF8E-4816-8010-7EBD40B288CC Q35775223-CC56C8A4-485F-4501-94A1-4196B202B1FE Q35808372-638EE981-1D2E-4774-9B25-AD5BAA0AF346 Q35907001-F340AAD9-25A6-40DA-AC66-1F93AD335820 Q36218446-7CBA91A7-3FF2-49D5-82B3-F70483BFA127 Q36315490-9F461D63-B532-410B-A5E9-3A6F3E0320CD Q36372962-956A7AAE-02C6-4078-9AA6-D9F79F224F5E Q36671223-12D4ED50-2454-4875-B08D-A623C1CC1E71 Q36805092-8AEB12E2-FFC5-4706-8A79-BDCD6E645C8C Q36897736-6B8A711E-1A21-4EDB-B574-3DC32A5A8343 Q37129828-D22C8D9D-F629-48BE-92E4-60368B9321DF Q37356474-01D596D9-B32C-482E-961A-AC3D12B3E19D Q37564411-61FDF852-1EA2-46A6-BC65-140148DF4ABA Q37679492-1C60D9C6-C730-48CC-9554-13352975BBC4 Q37847568-6FB433C4-94D5-4E22-8384-0A31D0AB7F21 Q37909897-714BA81C-81C6-40C6-9CD2-5B633084827C Q38039167-0E4977FB-DC0A-4B7D-A8A7-DA9ED7AF8BD1 Q38732720-E7E754D5-5684-4D5F-B2F3-62768A15A0B4 Q44256039-E4B55401-A036-483F-AA01-BBD1A079C9AA Q46581570-C80D9F1D-E0E8-446D-B1AF-4F52752F22EC Q47635634-458A9757-30F0-4C3D-BC01-4FEA1B80BC14 Q48194878-79F50C91-04EE-453A-8C91-32AF4055B36E Q53757323-7B7D1A27-EA45-4FF2-9EBA-860E436CA3E8 Q55110010-941C07CD-DB59-45BF-9365-7C85A3777585 Q55349797-7BCCE99C-6411-4AE5-8218-A29F6ADF9217 Q57137351-92CD57C9-5DC7-464A-B6BE-BE1C05014FBF Q57902945-5C417D7F-F77A-43D8-8DF8-2852F47CC870

P2860

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

http://www.wikidata.org/entity/Q36916140

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

@en

type

label

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

@en

prefLabel

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

@en

P1433

Q36916140-6C6D570B-28B3-4E1A-A280-EEC5F82C764B

P1476

Q36916140-6CD569BE-AAFE-4C98-B767-C3737E0D10A1

P2093

Q36916140-119D6C59-AEB7-4BB6-8C8D-3B15D19C6B7B

Q36916140-19F680D8-917F-4DA6-B96A-A1FF5245ECB5

Q36916140-2A92BCB6-50AE-4EA7-868D-0F20CB474262

Q36916140-32EFE0C0-6DF8-4C13-A278-A0647B27E01A

Q36916140-37E0D875-696C-4199-8E83-52913ED5B864

Q36916140-567D88A1-5D6E-496D-8C0D-6914BC7423FA

Q36916140-5DFA0B7B-D551-4DDA-A2C9-2E343E2C37F2

Q36916140-8E6A8883-A136-4C16-9ECC-AB9E03644386

Q36916140-97124466-7D62-4C21-B6DE-E6BA8973CD06

Q36916140-99C1C06D-2A4E-4B96-A5D3-10C8F522AB71

P2860

Q36916140-0BB387A1-3D68-4F36-975D-F422D83C6A92

Q36916140-3900AFC4-4368-4AD8-AEB9-04AA2FCCFE4B

Q36916140-3A3E41C3-BC21-491F-82F6-EA771C7EF0E3

Q36916140-49358B05-EECF-4049-A075-67605DCDBD1E

Q36916140-7D043D5A-A9DC-4697-BA12-32F002EB3145

Q36916140-8E7B918F-E8E8-4E8F-9888-A7A097C75CF7

Q36916140-9F8F4704-7EF5-4F37-934E-94D32AED501B

Q36916140-AC8C7066-DA32-4D7C-9BA4-2DDB90752A56

Q36916140-AFC384A8-9AC5-4C45-BE03-DAD5C57737A2

Q36916140-B0CFEF3C-8D26-49F1-AFB3-4AC25FEBA993

P304

Q36916140-E56867AB-53B3-4D8B-A871-2773DD8C5011

P31

Q36916140-57EAD937-D2A6-4A23-BA33-EA74FE525619

P356

Q36916140-5D5D4659-9E58-417E-B1A0-1A9FA8D7915E

P407

Q36916140-BCE9ADA3-CC74-4921-8678-F28DDD62FC4C

P433

Q36916140-C3F7768D-8250-4DC6-9DB1-839CF2A427FD

P478

Q36916140-17ACC53D-CCDB-4648-8E74-0C60CD233D7A

P50

Q36916140-3707AFFD-3736-4D56-AF9B-9D180F5BFA35

Q36916140-54874CE8-017B-42C4-92CE-F4647D8A178A

Q36916140-614A2559-5E58-43C9-9FC7-776E589E730A

Q36916140-6D133D2B-DD29-4DE0-951F-FC1CEBDEF06F

Q36916140-6EB6BA03-D3B6-44E9-825D-7A6D4FEDBD13

Q36916140-7F71B204-6A7C-4330-879E-9C866E2E76CF

P577

Q36916140-1A489756-F03F-4049-AC6E-BB149526F548

P5875

Q36916140-B9690E8B-8BDB-419E-A41A-60EAE50BF255

P698

Q36916140-853460E2-20D1-43B9-A81C-A1556F959E6D

P932

Q36916140-4248FCB3-0728-45FE-9C74-0696C7E53D6B

P356

P1433

Journal of the National Cancer Institute

P1476

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

@en

P2093

Andrea Eisen

http://www.w3.org/2001/XMLSchema#string

Barry Rosen

http://www.w3.org/2001/XMLSchema#string

Charmaine Kim-Sing

http://www.w3.org/2001/XMLSchema#string

Eitan Friedman

http://www.w3.org/2001/XMLSchema#string

Eliot Rosen

http://www.w3.org/2001/XMLSchema#string

Henry T Lynch

http://www.w3.org/2001/XMLSchema#string

Hereditary Breast Cancer Clinical Study Group

http://www.w3.org/2001/XMLSchema#string

Jacek Gronwald

http://www.w3.org/2001/XMLSchema#string

Jan Klijn

http://www.w3.org/2001/XMLSchema#string

Lucy Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Breast cancer and hormone-replacement therapy in the Million Women Study.

Endometrial cancer and hormone-replacement therapy in the Million Women Study.

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

P304

1361-1367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJN313

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Steven A. Narod

Siranoush Manoukian

Susan L Neuhausen

Claudine Isaacs

P577

2008-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23277580

http://www.w3.org/2001/XMLSchema#string

P698

18812548

http://www.w3.org/2001/XMLSchema#string

P932

2556701

http://www.w3.org/2001/XMLSchema#string